ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
June 13, 2023 02:00 ET
|
ITM Isotope Technologies Munich SE
New manufacturing plant in Neufahrn near Munich increases ITM's production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery ...
POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors
June 12, 2023 08:00 ET
|
POINT Biopharma
INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
June 07, 2023 07:00 ET
|
POINT Biopharma
Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”),...
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
May 25, 2023 08:30 ET
|
POINT Biopharma
PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25,...
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
May 15, 2023 07:35 ET
|
POINT Biopharma
INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global...
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 15, 2023 07:30 ET
|
POINT Biopharma
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023 Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer,...
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
April 24, 2023 07:30 ET
|
POINT Biopharma; Lantheus Holdings, Inc.
BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
April 04, 2023 08:00 ET
|
POINT Biopharma
BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an...
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
March 27, 2023 08:00 ET
|
POINT Biopharma
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH...
POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
March 07, 2023 07:45 ET
|
POINT Biopharma
INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...